{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-336772","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2026-08-06T11:45:16+00:00","discovered_at":"2026-08-06T11:50:01.430371+00:00","generated_at":"2026-08-06T11:50:07.523462+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Intellia reports positive Phase 3 HAELO data for lonvo-z; BLA submission expected H2 2026","bullets":["Phase 3 HAELO trial met primary endpoint: lonvo-z reduced HAE attacks by 87% vs placebo (p<0.0001); mean monthly attack rate 0.26 vs 2.10.","62% of lonvo-z patients attack-free and therapy-free for 6-month efficacy period vs 11% placebo; all key secondary endpoints met (p<0.0001).","Cash, cash equivalents and marketable securities $628.4M as of June 30, 2026, after $195M public offering; funds operations at least into 2028.","Net loss $106.6M in Q2 2026 vs $101.3M in Q2 2025; R&D expenses $82.6M, G&A expenses $37.8M due to commercial buildout.","Enrollment reinitiated in nex-z Phase 3 trials; genomic analysis identified HLA allele linked to liver transaminase elevations; HLA genotyping to be provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-336772","json":"https://secwatch.observer/filing/0001193125-26-336772.json","markdown":"https://secwatch.observer/filing/0001193125-26-336772.md","text":"https://secwatch.observer/filing/0001193125-26-336772.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526336772/0001193125-26-336772-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526336772/ntla-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:50:07.523462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}